• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在接受阿托伐醌预防治疗的免疫功能低下患者中检测到具有多重耐药突变的变体。

Variant With Multiple Resistance Mutations Detected in an Immunocompromised Patient Receiving Atovaquone Prophylaxis.

作者信息

Holbrook Nolan R, Klontz Erik H, Adams Gordon C, Schnittman Samuel R, Issa Nicolas C, Bond Sheila A, Branda John A, Lemieux Jacob E

机构信息

Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.

Infectious Diseases Division, Massachusetts General Hospital, Boston, Massachusetts, USA.

出版信息

Open Forum Infect Dis. 2023 Feb 23;10(3):ofad097. doi: 10.1093/ofid/ofad097. eCollection 2023 Mar.

DOI:10.1093/ofid/ofad097
PMID:36968958
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10034591/
Abstract

We report genomic sequences with multiple mutations in the atovaquone-target region of cytochrome b, including a newly identified Y272S mutation, plus 1 mutation of undetermined significance in the azithromycin-associated ribosomal protein L4. The parasite was sequenced from an immunocompromised patient on prophylactic atovaquone for pneumonia before diagnosis of babesiosis.

摘要

我们报告了细胞色素b的阿托伐醌靶区存在多个突变的基因组序列，包括一个新发现的Y272S突变，以及阿奇霉素相关核糖体蛋白L4中一个意义未明的突变。该寄生虫是从一名免疫功能低下的患者身上测序得到的，该患者在诊断巴贝斯虫病之前因预防肺炎而服用阿托伐醌。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ea/10034591/76a5e62f6101/ofad097f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ea/10034591/76a5e62f6101/ofad097f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ea/10034591/76a5e62f6101/ofad097f1.jpg

相似文献

1
Variant With Multiple Resistance Mutations Detected in an Immunocompromised Patient Receiving Atovaquone Prophylaxis.在接受阿托伐醌预防治疗的免疫功能低下患者中检测到具有多重耐药突变的变体。
Open Forum Infect Dis. 2023 Feb 23;10(3):ofad097. doi: 10.1093/ofid/ofad097. eCollection 2023 Mar.
2
Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection.免疫功能低下的微小巴贝斯虫感染患者对阿奇霉素-阿托伐醌耐药的出现。
Clin Infect Dis. 2010 Feb 1;50(3):381-6. doi: 10.1086/649859.
3
Combination of Clofazimine and Atovaquone as a Potent Therapeutic Regimen for the Radical Cure of Babesia microti Infection in Immunocompromised Hosts.氯法齐明与阿托伐醌联合应用于免疫抑制宿主巴贝虫微小亚种根治的强效治疗方案。
J Infect Dis. 2022 Jan 18;225(2):238-242. doi: 10.1093/infdis/jiab537.
4
Phosphatidylinositol 4-kinase is a viable target for the radical cure of infection in immunocompromised hosts.磷脂酰肌醇 4-激酶是免疫功能低下宿主根治感染的一个可行靶点。
Front Cell Infect Microbiol. 2022 Nov 14;12:1048962. doi: 10.3389/fcimb.2022.1048962. eCollection 2022.
5
Relapsed Infection Following Allogeneic Hematopoietic Cell Transplantation in a Patient With B-cell Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.B 细胞急性淋巴细胞白血病患者异基因造血细胞移植后的复发性感染：病例报告及文献复习
Open Forum Infect Dis. 2021 Jun 21;8(9):ofab323. doi: 10.1093/ofid/ofab323. eCollection 2021 Sep.
6
Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts.氯法齐明，一种治疗严重免疫功能低下宿主巴贝虫感染的有前景的药物。
J Infect Dis. 2020 Aug 17;222(6):1027-1036. doi: 10.1093/infdis/jiaa195.
7
A global map of genetic diversity in Babesia microti reveals strong population structure and identifies variants associated with clinical relapse.《微小巴贝斯虫的全球遗传多样性图谱揭示了强烈的种群结构，并鉴定出与临床复发相关的变异体。》
Nat Microbiol. 2016 Jun 13;1(7):16079. doi: 10.1038/nmicrobiol.2016.79.
8
Broad Antimicrobial Resistance in a Case of Relapsing Babesiosis Successfully Treated With Tafenoquine.用他非诺喹成功治疗的复发性巴贝斯虫病病例中的广泛抗菌药物耐药性
Clin Infect Dis. 2023 Feb 18;76(4):741-744. doi: 10.1093/cid/ciac473.
9
Treatment of refractory Babesia microti infection with atovaquone-proguanil in an HIV-infected patient: case report.艾滋病病毒感染患者使用阿托伐醌-氯胍治疗难治性微小巴贝斯虫感染：病例报告
Clin Infect Dis. 2007 Dec 15;45(12):1588-90. doi: 10.1086/523731.
10
Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia.利妥昔单抗和慢性淋巴细胞白血病相关复发性微小巴贝斯虫感染的阿托伐醌和阿奇霉素耐药的临床和分子证据。
Clin Infect Dis. 2017 Oct 1;65(7):1222-1225. doi: 10.1093/cid/cix477.

引用本文的文献

1
Efficacy and mechanism of action of cipargamin as an antibabesial drug candidate.西帕加明作为抗巴贝斯虫药物候选物的疗效及作用机制
Elife. 2025 Jun 19;13:RP101128. doi: 10.7554/eLife.101128.
2
Do Hosts Share a Blood Group System Gene Ortholog, Which Could Generate an Erythrocyte Antigen That Is Essential for Parasite Invasion?宿主是否共享一个血型系统基因直系同源物，该直系同源物是否能产生寄生虫入侵所必需的红细胞抗原？
Trop Med Infect Dis. 2024 Aug 26;9(9):195. doi: 10.3390/tropicalmed9090195.
3
Tafenoquine for Relapsing Babesiosis: A Case Series.

本文引用的文献

1
Human Babesiosis.人巴贝虫病。
Infect Dis Clin North Am. 2022 Sep;36(3):655-670. doi: 10.1016/j.idc.2022.02.009.
2
Broad Antimicrobial Resistance in a Case of Relapsing Babesiosis Successfully Treated With Tafenoquine.用他非诺喹成功治疗的复发性巴贝斯虫病病例中的广泛抗菌药物耐药性
Clin Infect Dis. 2023 Feb 18;76(4):741-744. doi: 10.1093/cid/ciac473.
3
Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone.使用他非诺喹治疗一名患有复发性巴贝斯虫病的患者，该患者具有对阿奇霉素和阿托伐醌耐药的临床及分子证据。
泰法诺喹治疗复发巴贝虫病：病例系列。
Clin Infect Dis. 2024 Jul 19;79(1):130-137. doi: 10.1093/cid/ciae238.
4
Plasma Blood Levels of Tafenoquine following a Single Oral Dosage in BALBc Mice with Acute Infection That Resulted in Rapid Clearance of Microscopically Detectable Parasitemia.在急性感染导致显微镜下可检测到的寄生虫血症迅速清除的BALB/c小鼠中单次口服剂量他非诺喹后的血浆血药浓度。
Pathogens. 2023 Aug 31;12(9):1113. doi: 10.3390/pathogens12091113.
5
Relapsing Babesiosis With Molecular Evidence of Resistance to Certain Antimicrobials Commonly Used to Treat Infections.复发性巴贝斯虫病，伴有对某些常用于治疗感染的抗菌药物耐药的分子证据。
Open Forum Infect Dis. 2023 Jul 20;10(8):ofad391. doi: 10.1093/ofid/ofad391. eCollection 2023 Aug.
IDCases. 2022 Feb 25;27:e01460. doi: 10.1016/j.idcr.2022.e01460. eCollection 2022.
4
Relapsed Infection Following Allogeneic Hematopoietic Cell Transplantation in a Patient With B-cell Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.B 细胞急性淋巴细胞白血病患者异基因造血细胞移植后的复发性感染：病例报告及文献复习
Open Forum Infect Dis. 2021 Jun 21;8(9):ofab323. doi: 10.1093/ofid/ofab323. eCollection 2021 Sep.
5
Cytochrome b Drug Resistance Mutation Decreases Babesia Fitness in the Tick Stages But Not the Mammalian Erythrocytic Cycle.细胞色素 b 药物抗性突变降低蜱阶段的疟原虫适应性，但不影响哺乳动物红细胞周期。
J Infect Dis. 2022 Jan 5;225(1):135-145. doi: 10.1093/infdis/jiab321.
6
Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis.美国传染病学会（IDSA）临床实践指南：2020 年巴贝虫病诊断与管理指南。
Clin Infect Dis. 2021 Jan 27;72(2):e49-e64. doi: 10.1093/cid/ciaa1216.
7
Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts.氯法齐明，一种治疗严重免疫功能低下宿主巴贝虫感染的有前景的药物。
J Infect Dis. 2020 Aug 17;222(6):1027-1036. doi: 10.1093/infdis/jiaa195.
8
Repeat exchange transfusion for treatment of severe babesiosis.重复换血疗法治疗重症巴贝斯虫病。
Transfus Apher Sci. 2019 Oct;58(5):638-640. doi: 10.1016/j.transci.2019.07.010. Epub 2019 Sep 5.
9
Risk Factors for Severe Infection, Hospitalization, and Prolonged Antimicrobial Therapy in Patients with Babesiosis.巴贝斯虫病患者发生严重感染、住院及延长抗菌治疗的危险因素
Am J Trop Med Hyg. 2017 Oct;97(4):1218-1225. doi: 10.4269/ajtmh.17-0146. Epub 2017 Jul 19.
10
Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia.利妥昔单抗和慢性淋巴细胞白血病相关复发性微小巴贝斯虫感染的阿托伐醌和阿奇霉素耐药的临床和分子证据。
Clin Infect Dis. 2017 Oct 1;65(7):1222-1225. doi: 10.1093/cid/cix477.